FIELD: chemistry.
SUBSTANCE: invention refers to new compounds of the formula (I) that are characterized by the properties of M3 muscarine receptor antagonist that is applicable in treatment or prevention of the disease or state (the abnormity of) which includes activity of the M3 muscarine receptor such as respiratory diseases. In the formula (I) 
A is represented by the oxygen atom or the group -N(R12)-; (i) R1 is represented by C1-C6-alkyl or the hydrogen atom; and R2 is represented by the hydrogen atom or the group -R5, -Z-Y-R5, -Z-NR9R10, -Z-NR9CO-R5 or -Z-CO2H; and R3 is absent or is represented by C1-C6-alkyl, and in this case the nitrogen atom to which it is bound is represented by tetradic nitrogen and bears a positive charge; or (ii) R1 and R2 together with nitrogen to which they are bound form heterocycloalkyl ring; the mentioned ring is displaced by the group -Y-R5 or -Z-Y-R5, and R3 is absent or is represented by C1-C6-alkyl, and in this case the nitrogen atom to which it is bound is represented by tetradic nitrogen and bears a positive charge; R4 is represented by the formula group (a), (b), (c) or (d); Z is represented by C1-C16-alkylene group; Y is represented by the link or the oxygen atom; R5 is represented by C1-C6-alkyl, aryl, phenyl condensed with C3-C6cycloalkyl, phenyl condensed with heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, C3-C6cycloalkyl or heteroC3-C6cycloalkyl group; R6 is represented by C1-C6-alkyl or the hydrogen atom; n and m equal 0; R8a and R8b are independently chosen from the group consisting of aryl, phenyl condensed with heterocycloalkyl, heteroaryl, C1-C6-alkyl, C3-C6cycloalkyl; R8c is represented by -OH or C1-C6-alkyl; R9 and R10 are represented independently by the hydrogen atom, C1-C6-alkyl, aryl, phenyl condensed with heterocycloalkyl and other components mentioned in the invention formula.
EFFECT: new compounds applicable in treatment or prevention of the disease or state (the abnormity of) which includes activity of the M3 muscarine receptor such as respiratory diseases.
10 cl, 49 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USING THEM FOR TREATING IMMUNOLOGICAL AND ONCOLOGICAL COMPOUNDS | 2009 |
|
RU2545023C9 |
| DERIVATIVES OF QUINUCLIDINE, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2282629C2 |
| AZOLE AND THIAZOLE DERIVATIVES AND USE THEREOF | 2006 |
|
RU2436779C2 |
| ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
| NOVEL ESTERS OF QUATERNISED QUINUCLIDINE | 2005 |
|
RU2382041C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| 1H-INDAZOLES, 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES, SYNTHESIS THEREOF AND USE | 2004 |
|
RU2389729C2 |
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
| SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE DERIVATIVES OF PYRIMIDINES, COMPOSITIONS THEREOF AND METHODS OF TREATING USE THEREOF | 2012 |
|
RU2697712C2 |
| CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
